Table 4.
Baseline characteristics of patients with liver cirrhosis and COVID-19 infection according to the presence of complications (n = 400)
| Characteristic | LC+ COVID+ | LC− COVID+ | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Complications+ (n = 18) | Complications− (n = 49) | p value | Complications+ (n = 60) | Complications− (n = 273) | p value | |
| Male sex | 12 (66.7) | 28 (57.1) | 0.48 | 33 (55.0) | 167 (61.2) | 0.38 |
|
| ||||||
| Age, yr | 68.9 ± 13.0 | 56.6 ± 15.4 | < 0.01 | 71.8 ± 13.0 | 57.2 ± 14.8 | < 0.01 |
|
| ||||||
| Region of diagnosis | ||||||
|
| ||||||
| Daegu & Gyeongbuk | 7 (38.9) | 17 (34.7) | 0.75 | 43 (71.7) | 172 (63.0) | 0.20 |
|
| ||||||
| Testing hospital | ||||||
|
| ||||||
| 3rd, % | 5 (27.8) | 4 (8.2) | 0.05 | 12 (20.0) | 31 (11.4) | 0.07 |
|
| ||||||
| Comorbidities | ||||||
|
| ||||||
| Decompensated liver cirrhosis | 7 (38.9) | 12 (24.5) | 0.25 | 0 | 0 | - |
|
| ||||||
| Diabetes | 8 (44.4) | 13 (26.5) | 0.16 | 21 (35.0) | 47 (17.2) | < 0.01 |
|
| ||||||
| Hypertension | 12 (66.7) | 15 (30.6) | < 0.01 | 35 (58.3) | 100 (36.6) | < 0.01 |
|
| ||||||
| Dyslipidemia | 5 (27.8) | 14 (28.6) | 0.95 | 31 (51.7) | 85 (31.1) | < 0.01 |
|
| ||||||
| Cardiovascular disease | 3 (16.7) | 6 (12.2) | 0.69 | 12 (20.0) | 32 (11.7) | 0.09 |
|
| ||||||
| Cancer | 8 (44.4) | 4 (8.2) | < 0.01 | 7 (11.7) | 13 (4.8) | 0.06 |
|
| ||||||
| COPD | 7 (38.9) | 2 (4.1) | < 0.01 | 16 (26.7) | 38 (13.9) | 0.02 |
|
| ||||||
| Asthma | 4 (22.2) | 8 (16.3) | 0.72 | 12 (20.0) | 40 (14.7) | 0.30 |
|
| ||||||
| ESRD with dialysis | 0 | 0 (0) | - | 0 | 0 | - |
|
| ||||||
| Immunocompromised status | 1 (5.6) | 8 (16.3) | 0.43 | 2 (3.3) | 11 (4.0) | 1.00 |
|
| ||||||
| CCI | 5.6 ± 3.1 | 3.9 ± 2.4 | 0.02 | 3.5 ± 2.3 | 1.9 ± 2.0 | < 0.01 |
Values are presented as number (%) or mean ± standard deviation.
COVID-19, coronavirus disease 2019; LC, liver cirrhosis; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; CCI, Charlson comorbidity index.